Sen. John Boozman Purchases Shares of DexCom, Inc. (NASDAQ:DXCM)

Senator John Boozman (R-Arkansas) recently bought shares of DexCom, Inc. (NASDAQ:DXCM). In a filing disclosed on February 15th, the Senator disclosed that they had bought between $1,001 and $15,000 in DexCom stock on January 26th.

Senator John Boozman also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Omnicom Group (NYSE:OMC) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Eaton (NYSE:ETN) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Caterpillar (NYSE:CAT) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of iShares S&P 500 Growth ETF (NYSEARCA:IVW) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Fiserv (NASDAQ:FISV) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Union Pacific (NYSE:UNP) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of CVS Health (NYSE:CVS) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of PayPal (NASDAQ:PYPL) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Micron Technology (NASDAQ:MU) on 1/26/2026.
• Sold $1,001 – $15,000 in shares of abrdn Physical Palladium Shares ETF (NYSEARCA:PALL) on 1/23/2026.

DexCom Stock Performance

Shares of DXCM stock opened at $73.08 on Friday. The company has a fifty day moving average price of $69.49 and a two-hundred day moving average price of $69.35. DexCom, Inc. has a one year low of $54.11 and a one year high of $91.87. The stock has a market cap of $28.13 billion, a P/E ratio of 34.80, a P/E/G ratio of 1.41 and a beta of 1.49. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.88 and a quick ratio of 1.59.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.03. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The company had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same period in the previous year, the business earned $0.45 EPS. DexCom’s revenue for the quarter was up 13.1% compared to the same quarter last year. As a group, equities analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Wells Fargo & Company cut their target price on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a research note on Friday, February 13th. Canaccord Genuity Group set a $95.00 price target on shares of DexCom and gave the company a “buy” rating in a report on Friday, February 13th. Weiss Ratings cut DexCom from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday. Evercore initiated coverage on DexCom in a research report on Tuesday, November 25th. They issued an “in-line” rating and a $68.00 target price on the stock. Finally, Barclays reiterated an “underweight” rating and set a $72.00 target price (up previously from $71.00) on shares of DexCom in a research note on Friday, February 13th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $85.18.

Institutional Investors Weigh In On DexCom

A number of hedge funds and other institutional investors have recently made changes to their positions in DXCM. Jennison Associates LLC increased its stake in DexCom by 9.4% in the second quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock valued at $1,005,367,000 after acquiring an additional 994,300 shares during the last quarter. Marshall Wace LLP lifted its stake in DexCom by 260.7% during the second quarter. Marshall Wace LLP now owns 3,822,085 shares of the medical device company’s stock worth $333,630,000 after purchasing an additional 2,762,504 shares during the last quarter. E. Ohman J or Asset Management AB lifted its stake in DexCom by 400.2% during the third quarter. E. Ohman J or Asset Management AB now owns 77,492 shares of the medical device company’s stock worth $5,214,000 after purchasing an additional 62,000 shares during the last quarter. Zevenbergen Capital Investments LLC boosted its holdings in shares of DexCom by 10.0% in the 3rd quarter. Zevenbergen Capital Investments LLC now owns 685,433 shares of the medical device company’s stock valued at $46,123,000 after purchasing an additional 62,098 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of DexCom by 11.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 212,045 shares of the medical device company’s stock worth $14,269,000 after buying an additional 21,352 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

About Senator Boozman

John Boozman (Republican Party) is a member of the U.S. Senate from Arkansas. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Boozman (Republican Party) ran for re-election to the U.S. Senate to represent Arkansas. He won in the general election on November 8, 2022. Boozman won re-election in 2016. He faced Democrat Conner Eldridge, Libertarian Frank Gilbert, and write-in candidate Jason Tate in the general election. Arkansas’ U.S. Senate race was rated as safely Republican in 2016. Boozman began his political career in the U.S. House. He won a special election in 2001 and served in that position until his election to the Senate in 2010. Prior to his political career, Boozman worked as an optometrist. As of a 2014 analysis of multiple outside rankings, Boozman is an average Republican member of Congress, meaning he will vote with the Republican Party on the majority of bills. Below is an abbreviated outline of Boozman’s academic, professional, and political career: 2011-Present: U.S. Senator from Arkansas 2001-2011: U.S. Representative from Arkansas 1977: Graduated from Southern College of Optometry

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.